J., Ferguson, M., Prins, J
The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)
This trial underscores the expanding scope of incretin therapy beyond simple weight management, a trend also visible in the growing body of research on peptides for athletic performance and recovery
From beauty habits and first impressions to behind-the-scenes stories from The Invite, the co-stars answer revealing questions and share candid confessions
Their benefits are mediated through diverse mechanisms, including modulation of the gut microbiota, competitive exclusion of pathogens, regulation of immune and inflammatory pathways, and interactions with host metabolism and the gutbrain axis